[18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer

Vrachimis, Alexis; Burg, Matthias C.; Wenning, Christian; Allkemper, Thomas; Weckesser, Matthias; Schäfers, Michael; Stegger, Lars

doi:10.1007/s00259-015-3195-2

Cited by 42 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PET can also be performed with iodine-124 ( I not only because it provides tomographic images, but 124 I PET also offers higher resolution (117,118,119). Nonetheless, it has also been associated with false-negative findings in patients with miliary lung nodules (120).…”

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

“…The half-life of 124 I (4.2 days) allows the acquisition of sequential images for uptake quantification over time. 124 I PET-guided lesional 3D dosimetry together with blood clearance studies can predict the absorbed lesion dose, improve selection of the safest and most effective 131 I activity to administer, and predict responses to RAI treatment (121,122). Nowadays, 124 I PET is used almost exclusively in research settings owing to the limited availability of the tracer and the growing use of SPECT-CT for post-therapeutic 131 I scan.…”

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

“…124 I PET-guided lesional 3D dosimetry together with blood clearance studies can predict the absorbed lesion dose, improve selection of the safest and most effective 131 I activity to administer, and predict responses to RAI treatment (121,122). Nowadays, 124 I PET is used almost exclusively in research settings owing to the limited availability of the tracer and the growing use of SPECT-CT for post-therapeutic 131 I scan. 18 F-Fluoride PET has been proposed for evaluating bone metastases from thyroid cancer, but the lytic nature of these lesions makes their evaluation difficult (123).…”

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

See 2 more Smart Citations

ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach

Lamartina¹,

Deandreis

Durante³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

The clinical and epidemiological profiles of differentiated thyroid cancers (DTCs) have changed in the last three decades. Today's DTCs are more likely to be small, localized, asymptomatic papillary forms. Current practice is, though, moving toward more conservative approaches (e.g. lobectomy instead of total thyroidectomy, selective use of radioiodine). This evolution has been paralleled and partly driven by rapid technological advances in the field of diagnostic imaging. The challenge of contemporary DTCs follow-up is to tailor a risk-of-recurrence-based management, taking into account the dynamic nature of these risks, which evolve over time, spontaneously and in response to treatments. This review provides a closer look at the evolving evidence-based views on the use and utility of imaging technology in the post-treatment staging and the short-and long-term surveillance of patients with DTCs. The studies considered range from cervical US with Doppler flow analysis to an expanding palette of increasingly sophisticated second-line studies (cross-sectional, functional, combined-modality approaches), which can be used to detect disease that has spread beyond the neck and, in some cases, shed light on its probable outcome.

show abstract

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

Section: Other Radiopharmaceuticalsmentioning

confidence: 99%

See 1 more Smart Citation

ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach

Lamartina¹,

Deandreis

Durante³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In DTC, PET/MRI showed equal performance of detecting local relapse, lymph node, and bone metastases. However, PET/CT was superior to PET/MRI to detect pulmonary metastatic lesions [40].…”

Section: Head and Neck Cancermentioning

confidence: 99%

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Kwon

Becker

Goo

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. 18F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

show abstract

“…

A closer look at the data proffered by Vrachimis et al reveals that the poorer performance of PET/MRI compared to PET/CT for this indication resides in its shortcomings in the ability to diagnose pulmonary metastases, a frequent occurrence in progressive thyroid carcinoma.

…”

mentioning

confidence: 99%

PET/MRI and PET/CT: is there room for both at the top of the food chain?

Kuwert

Ritt

2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In this issue of the journal, Vrachimis and colleagues demonstrate that positron emission tomography combined with Xray computed tomography (PET/CT) outperforms PET combined with magnetic resonance imaging (PET/MRI) in restaging radioiodine-negative patients with biochemical relapse of differentiated thyroid carcinoma [1]. This comes as a surprise, at least to the uninitiated: In a world predominantly driven by material considerations, common sense would presume that diagnostic accuracy correlates with costs, and PET/ MRI indeed Boutperforms^PET considerably with regard to its demands on resources spent on acquisition and operation.A closer look at the data proffered by Vrachimis et al. reveals that the poorer performance of PET/MRI compared to PET/CT for this indication resides in its shortcomings in the ability to diagnose pulmonary metastases, a frequent occurrence in progressive thyroid carcinoma. MRI aficionados will argue that this problem may be overcome by using MRI sequences dedicated to lung imaging. This contingent may ultimately be correct, but such arguments are purely speculative at the moment, as empirical proof for the case of PET/MRI is lacking.A comprehensive review on the evidence reporting the use of PET/MRI in a clinical setting is beyond the scope of this editorial. However, a short appraisal of the hitherto published literature comparing the utility of PET/MRI and PET/CT can be attempted: At the time of this writing, 166 papers featuring the keyword combination BPET/MR PET/CT^currently reside in the Web of Science (ISI) Internet library. Of these, roughly 22 are original articles comparing the diagnostic performance of these two hybrid imaging modalities in oncology. Six report data from mixed groups of patients [2][3][4][5][6][7], with five finding an equivalence of diagnostic performance of the two hybrid imaging technologies and one a slight superiority of PET/MRI over PET/CT with regard to influence on further clinical management. None deals with thyroid cancer directly, allowing us to consider the new publication under discussion by Vrachimis et al. the first to study this neoplastic entity specifically. However, the utility of PET/MRI and PET/CT to detect and characterize small pulmonary nodules more generally has been previously investigated in three papers, with the data tipping the scales in favour of PET/CT [8][9][10]. The remaining 13 publications report some evidence that PET/ MRI is superior to PET/CT for characterizing primary tumours, e.g. primary bone tumours [11][12][13] or oesophageal carcinoma [14], but do not demonstrate significant advantages of whole-body MRI over whole-body PET/CT for N or M staging [15][16][17][18][19][20][21][22][23][24].The introduction of PET/MRI was heralded as a technological breakthrough, and many expected a subsequent clinical revolution, with the newer modality vying to supersede PET/CT atop the diagnostic food chain just as the Burmese python is supplanting the American alligator in the Florida Everglades. However, none of the above-mention...

show abstract

[18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer

Cited by 42 publications

References 24 publications

ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach

ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

PET/MRI and PET/CT: is there room for both at the top of the food chain?

Contact Info

Product

Resources

About